Suppr超能文献

通过基于配体的药效团建模和分子对接研究,在计算机上鉴定小分子苯并呋喃-1,2,3-三唑杂化物作为肺癌中靶向表皮生长因子受体(EGFR)的潜在抑制剂。

In-silico identification of small molecule benzofuran-1,2,3-triazole hybrids as potential inhibitors targeting EGFR in lung cancer via ligand-based pharmacophore modeling and molecular docking studies.

作者信息

Kumar Sunil, Ali Iqra, Abbas Faheem, Khan Nimra, Gupta Manoj K, Garg Manoj, Kumar Saroj, Kumar Deepak

机构信息

Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Shoolini University, Solan, Himachal Pradesh 173229 India.

Department of Biosciences, COMSATS University Islamabad, Islamabad Campus, Islamabad, 45550 Pakistan.

出版信息

In Silico Pharmacol. 2023 Aug 9;11(1):20. doi: 10.1007/s40203-023-00157-1. eCollection 2023.

Abstract

UNLABELLED

Lung cancer is one of the most common and deadly types of cancer worldwide, and the epidermal growth factor receptor (EGFR) has emerged as a promising therapeutic target for the treatment of this disease. In this study, we designed a library of 1840 benzofuran-1,2,3-triazole hybrids and conducted pharmacophore-based screening to identify potential EGFR inhibitors. The 20 identified compounds were further evaluated using molecular docking and molecular dynamics simulations to understand their binding interactions with the EGFR receptor. In-silico ADME and toxicity studies were also performed to assess their drug-likeness and safety profiles. The results of this study showed the benzofuran-1,2,3-triazole hybrids BENZ-0454, BENZ-0143, BENZ-1292, BENZ-0335, BENZ-0332, and BENZ-1070 dock score of - 10.2, - 10, - 9.9, - 9.8, - 9.7, - 9.6, while reference molecule - 7.9 kcal/mol for EGFR (PDB ID: 4HJO) respectively. The molecular docking and molecular dynamics simulations revealed that the identified compounds formed stable interactions with the active site of the receptor, indicating their potential as inhibitors. The in-silico ADME and toxicity studies suggested that the compounds had good pharmacokinetic and safety profiles, further supporting their potential as therapeutic agents. Finally, performed DFT studies on the best-selected ligands to gain further insights into their electronic properties. The findings of this study provide important insights into the potential of benzofuran-1,2,3-triazole hybrids as promising EGFR inhibitors for the treatment of lung cancer. Overall, this study provides a valuable starting point for the development of novel EGFR inhibitors with improved efficacy and safety profiles.

SUPPLEMENTARY INFORMATION

The online version contains supplementary material available at 10.1007/s40203-023-00157-1.

摘要

未标注

肺癌是全球最常见且致命的癌症类型之一,表皮生长因子受体(EGFR)已成为治疗该疾病的一个有前景的治疗靶点。在本研究中,我们设计了一个包含1840种苯并呋喃 - 1,2,3 - 三唑杂化物的文库,并基于药效团进行筛选以鉴定潜在的EGFR抑制剂。对鉴定出的20种化合物进一步使用分子对接和分子动力学模拟进行评估,以了解它们与EGFR受体的结合相互作用。还进行了计算机辅助的ADME和毒性研究,以评估它们的药物相似性和安全性概况。本研究结果显示,苯并呋喃 - 1,2,3 - 三唑杂化物BENZ - 0454、BENZ - 0143、BENZ - 1292、BENZ - 0335、BENZ - 0332和BENZ - 1070与EGFR(PDB ID:4HJO)的对接分数分别为 - 10.2、 - 10、 - 9.9、 - 9.8、 - 9.7、 - 9.6,而参考分子为 - 7.9千卡/摩尔。分子对接和分子动力学模拟表明,鉴定出的化合物与受体活性位点形成稳定相互作用,表明它们具有作为抑制剂的潜力。计算机辅助的ADME和毒性研究表明,这些化合物具有良好的药代动力学和安全性概况,进一步支持了它们作为治疗剂的潜力。最后,对最佳选择的配体进行了密度泛函理论(DFT)研究,以进一步深入了解其电子性质。本研究结果为苯并呋喃 - 1,2,3 - 三唑杂化物作为治疗肺癌的有前景的EGFR抑制剂的潜力提供了重要见解。总体而言,本研究为开发具有更高疗效和安全性概况的新型EGFR抑制剂提供了有价值的起点。

补充信息

在线版本包含可在10.1007/s40203 - 023 - 00157 - 1获取的补充材料。

相似文献

引用本文的文献

本文引用的文献

3
Advances in Lung Cancer Treatment Using Nanomedicines.肺癌纳米药物治疗进展
ACS Omega. 2022 Dec 29;8(1):10-41. doi: 10.1021/acsomega.2c04078. eCollection 2023 Jan 10.
4
Radon and Lung Cancer: Current Trends and Future Perspectives.氡与肺癌:当前趋势及未来展望
Cancers (Basel). 2022 Jun 27;14(13):3142. doi: 10.3390/cancers14133142.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验